Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
April 24 2023 - 4:01PM
Business Wire
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a
clinical-stage biopharmaceutical company developing a broad
pipeline of novel immunotherapies by applying its proprietary
technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor
Activated Immunomodulator (TRACIr) platforms, today announced that
Janux management will participate at two upcoming investor
conferences and be available for 1x1 meetings. Details of the
conferences are as follows:
H.C. Wainwright BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 2 Time: 8am to 5pm ET Forum: 1x1 meetings
Location: NASDAQ World Headquarters, New York, NY
BofA Securities 2023 Health Care Conference Dates:
Tuesday, May 9 to Thursday, May 11 Forum: 1x1 meetings and
corporate presentation Presentation Time: Wednesday, May 10 at 5pm
PT Location: Encore Hotel, Las Vegas, NV
Janux’s TRACTr and TRACIr Pipeline
JANX008 is a TRACTr that targets EGFR and is being studied in a
Phase 1 clinical trial for the treatment of multiple solid cancers
including colorectal cancer, squamous cell carcinoma of the head
and neck, non-small cell lung cancer, and renal cell carcinoma.
Janux’s first clinical candidate, JANX007, is a TRACTr that targets
PSMA and is being investigated in a Phase 1 clinical trial in adult
subjects with metastatic castration-resistant prostate cancer
(mCRPC). Janux’s TRACIr drug candidate, JANX009, is designed for
targeting both the programmed death-ligand 1 (PD-L1) receptor as
well as the costimulatory CD28 receptor on T cells and is being
investigated in preclinical studies for the treatment of solid
tumors. Janux is also applying its proprietary technology to
develop a TRACTr designed to target TROP2, a clinically validated
anti-tumor target that is overexpressed in various cancer types,
such as breast, lung, urothelial, endometrial, ovarian, prostate,
pancreatic, gastric, colon, head and neck, and glioma. In addition
to named programs, Janux is generating a number of unnamed TRACTr
and TRACIr programs for potential future development.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing
next-generation bispecific immunotherapies with the goal of
fighting cancers by killing tumor cells while allowing healthy
tissues to remain unharmed. Janux’s proprietary platforms develop
unique Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated
Immunomodulators (TRACIr) and support the building of a broad
pipeline of drugs designed to direct and guide the patient’s immune
system to eradicate tumors while minimizing safety concerns. The
company's innovative technology currently focuses on the
engineering of bispecific antibodies functional only in the tumor,
providing safety advantages compared to earlier generations of
bispecific immunotherapies. Currently, Janux’s two lead TRACTr
compounds for PSMA and EGFR are in the clinic. For more
information, please visit www.januxrx.com and follow us on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230424005872/en/
Investors: Andy Meyer Janux Therapeutics
ameyer@januxrx.com (202) 215-2579
Media: Jessica Yingling, Ph.D. Little Dog Communications
Inc. jessica@litldog.com (858) 344-8091
Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
From Apr 2023 to Apr 2024